- Pervistop®, the once-daily supplement specifically designed to control persistent HPV, is now available with exclusive worldwide distribution rights.
Lo.Li. Pharma International will present an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners. Pervistop® promises to be an extremely effective tool in the management of an extremely unpredictable disease
FRANKFURT, Germany, Nov. 1, 2022 /PRNewswire/ -- Lo.Li. Pharma International announces a highly anticipated new product pre-launch at CPHI 2022, filling a latent and unmet clinical need for human papillomavirus (HPV) patients. As the largest pharmaceutical industry event worldwide, CPHI Frankfurt will allow thousands of participants to learn for the first time about this innovative product, whose exclusive formula helps counteract the signs, symptoms and persistence of HPV.
According to the National Foundation for Infectious Diseases, about 80% of sexually active women and men become infected with HPV at some point in their lives. HPV is the most common sexually transmitted infection worldwide and is known to cause certain types of cancer and genital warts.
"We know that 95% of cervical cancer is due to human papillomavirus and that cervical cancer is almost entirely preventable," said Samanta De Filippi, General Manager of Lo.Li. Pharma International. "Pervistop® offers a true alternative to eradicate the root problem of HPV persistence, which can unpredictably evolve into cancer."
During this pre-launch phase, Lo.Li. Pharma International will focus on creating strategic alliances with companies that are committed to offering innovative options in their local market and are already well versed in the gynecological therapeutic area.
De Filippi explained: "Having launched Pervistop® on the Italian market, we know the difficulties HPV patients face and the hopelessness women feel when they have a persistent HPV diagnosis. Lo.Li. Pharma Group was the first to offer an EGCG-based supplement for HPV patients in Italy, and our partners can also be the first and only ones in their markets."
Contact Raffaele Secchi, who is leading the project, to learn more about Pervistop® and global partnership opportunities:
Raffaele SecchiDirector of Business Development r.secchi@lolipharmainternational.com
About Lo.Li. Pharma International
Staying competitive in crowded markets is not easy, and innovating through in-house product development can be costly and risky. In addition, many nutraceutical and medical device development companies do not invest in sound clinical research, which could negatively affect the market success of licensed products. Lo.Li. Pharma International is a branch of Lo.Li. Pharma Srl, a growing healthcare company based in Rome, dedicated to the research, development and distribution of innovative, clinically tested and proven functional dietary supplements and medical devices. As world-renowned experts in inositol and basic nutraceutical science and research, Lo.Li. Pharma International is committed to supporting our partners through exclusive and equitable distribution agreements, while sharing the scientific knowledge and marketing strategies needed to be successful. For more information visit: www.lolipharmainternational.com
Photo - linkLogo - link
Media Contact:Micaela SadowskiLo.Li. Pharma Internationalm.sadowski@lolipharmainternational.comt. 39 06.88379670 Extension 33
View original content: enlace
